An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome

References

• Finn O. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23:6–31. doi:10.1093/annonc/mds256.
   PubMed Web of Science ®Google Scholar
• Roderburg C, Luedde T. The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma. Gut Microbes. 2014; 5(4):441–445. doi:10.4161/gmic.29599.
   PubMed Web of Science ®Google Scholar
• Mima K, Ogino S, Nakagawa S, Sawayama H, Kinoshita K, Krashima R, Ishimoto T, Imai K, Iwatsuki M, Hashimoto D. The role of intestinal bacteria in the development and progression of gastrointestinal tract neoplasms. Surg Oncol. 2017;26:368–376. doi:10.1016/j.suronc.2017.07.011.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020; 17(8):807–821. doi:10.1038/s41423-020-0488-6.
   PubMed Web of Science ®Google Scholar
• Bhutiani N, Wargo JA. Gut microbes as biomarkers of ICI response—sharpening the focus. Nat Rev Clin Oncol. 2022; 19(8):495–496. doi:10.1038/s41571-022-00634-0.
   PubMed Web of Science ®Google Scholar
• Salminen SJ, Gueimonde M, Isolauri E. Probiotics that modify disease risk. J Nutr. 2005;135:1294–1298. doi:10.1093/jn/135.5.1294.
   PubMed Web of Science ®Google Scholar
• Roberfroid MB. Prebiotics and probiotics: are they functional foods? Am J Clin Nutr. 2000;71:1682S–1687S. doi:10.1093/ajcn/71.6.1682S.
   PubMed Web of Science ®Google Scholar
• Ma W, Mao Q, Xia W, Dong G, Yu C, Jiang F. Gut microbiota shapes the efficiency of cancer therapy. Front Microbiol. 2019;10:1050. doi:10.3389/fmicb.2019.01050.
   PubMed Web of Science ®Google Scholar
• Sanders ME, Merenstein DJ, Reid G, Gibson GR, Rastall RA. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic. Nat Rev Gastroenterol Hepatol. 2019; 16(10):605–616. doi:10.1038/s41575-019-0173-3.
   PubMed Web of Science ®Google Scholar
• Sharon G, Sampson TR, Geschwind DH, Mazmanian SK. The central nervous system and the gut microbiome. Cell. 2016; 167(4):915–932. doi:10.1016/j.cell.2016.10.027.
   PubMed Web of Science ®Google Scholar
• Nagpal R, Mainali R, Ahmadi S, Wang S, Singh R, Kavanagh K, Kitzman DW, Kushugulova A, Marotta F, Yadav H. Gut microbiome and aging: Physiological and mechanistic insights. J Nutr Health Aging. 2018; 4(4):267–285. doi:10.3233/NHA-170030.
   Google Scholar
• Dey N, Ciorba MA. Probiotic gut bacteria enhance cancer immunotherapy in a mouse model of melanoma. Gastroenterology. 2016; 151(1):206–207. doi:10.1053/j.gastro.2016.05.015.
   PubMedGoogle Scholar
• Patil A. Probiotics in cancer treatment: from the laboratory to clinical practice. Preprints. 2023. doi:10.20944/preprints202307.0553.v1.
   Google Scholar
• Gao G, Shen S, Zhang T, Zhang J, Huang S, Sun Z, Zhang H. Lacticaseibacillus rhamnosus Probio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites. EBioMedicine. 2023;91:91. doi:10.1016/j.ebiom.2023.104533.
   Web of Science ®Google Scholar
• Bender MJ, AC M, Phelps CM, Pandey SP, Laughlin CR, Shapira JH, Sanchez LM, Rana M, Richie TG, Mims TS. Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell. 2023; 186(9):1846–1862. e26. doi:10.1016/j.cell.2023.03.011.
   PubMed Web of Science ®Google Scholar
• Liu F, Li J, Guan Y, Lou Y, Chen H, Xu M, Deng D, Chen J, Ni B, Zhao L. Dysbiosis of the gut microbiome is associated with tumor biomarkers in lung cancer. Int J Biol Sci. 2019; 15(11):2381–2392. doi:10.7150/ijbs.35980.
   PubMed Web of Science ®Google Scholar
• Olovo CV, Huang X, Zheng X, Xu M. Faecal microbial biomarkers in early diagnosis of colorectal cancer. J Cell Mol Med. 2021;25:10783–10797. doi:10.1111/jcmm.17010.
   PubMed Web of Science ®Google Scholar
• Sheflin AM, Whitney AK, Weir TL. Cancer-promoting effects of microbial dysbiosis. Curr Oncol Rep. 2014; 16(10):1–9. doi:10.1007/S11912-014-0406-0.
   Web of Science ®Google Scholar
• Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? revisiting the ratio of bacterial to host cells in humans. Cell. 2016; 164(3):337–340. doi:10.1016/j.cell.2016.01.013.
   PubMed Web of Science ®Google Scholar
• Cani PD, Moens de Hase E, Van Hul M. Gut microbiota and host metabolism: from proof of concept to therapeutic intervention. Microorganisms. 2021; 9(6):1302. doi:10.3390/microorganisms9061302.
   PubMed Web of Science ®Google Scholar
• Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. Nat Rev Microbiol. 2021; 19(1):55–71. doi:10.1038/s41579-020-0433-9.
   PubMed Web of Science ®Google Scholar
• Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014; 157(1):121–141. doi:10.1016/j.cell.2014.03.011.
   PubMed Web of Science ®Google Scholar
• Jiang S, Chen D, Ma C, Liu H, Huang S, Zhang J. Establishing a novel inflammatory bowel disease prediction model based on gene markers identified from single nucleotide variants of the intestinal microbiota. iMeta. 2022; 1(3):e40. doi:10.1002/imt2.40.
   Google Scholar
• Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020; 17(4):223–237. doi:10.1038/s41575-019-0258-z.
   PubMed Web of Science ®Google Scholar
• Van Hul M, Cani PD. The gut microbiota in obesity and weight management: microbes as friends or foe? Nat Rev Endocrinol. 2023; 19(5):258–271. doi:10.1038/s41574-022-00794-0.
   PubMed Web of Science ®Google Scholar
• Das T, Jayasudha R, Chakravarthy S, Prashanthi GS, Bhargava A, Tyagi M, Rani PK, Pappuru RR, Sharma S, Shivaji S. Alterations in the gut bacterial microbiome in people with type 2 diabetes mellitus and diabetic retinopathy. Sci Rep. 2021; 11(1):2738. doi:10.1038/s41598-021-82538-0.
   PubMed Web of Science ®Google Scholar
• Jiang S, Liu A, Ma W, Liu X, Luo P, Zhan M, Zhou X, Chen L, Zhang J. Lactobacillus gasseri CKCC1913 mediated modulation of the gut–liver axis alleviated insulin resistance and liver damage induced by type 2 diabetes. Food Funct. 2023; 14(18):8504–8520. doi:10.1039/d3fo01701j.
   PubMed Web of Science ®Google Scholar
• Miyauchi E, Shimokawa C, Steimle A, Desai MS, Ohno H. The impact of the gut microbiome on extra-intestinal autoimmune diseases. Nat Rev Immunol. 2023; 23(1):9–23. doi:10.1038/s41577-022-00727-y.
   PubMed Web of Science ®Google Scholar
• Li B, Selmi C, Tang R, Gershwin ME, Ma X. The microbiome and autoimmunity: a paradigm from the gut–liver axis. Cell Mol Immunol. 2018; 15(6):595–609. doi:10.1038/cmi.2018.7.
   PubMed Web of Science ®Google Scholar
• Iweala OI, Nagler CR. The microbiome and food allergy. Annu Rev Immunol. 2019; 37(1):377–403. doi:10.1146/annurev-immunol-042718-041621.
   PubMedGoogle Scholar
• Wang M, Karlsson C, Olsson C, Adlerberth I, Wold AE, Strachan DP, Martricardi PM, Aberg N, Perkin MR, Tripodi S. et al. Reduced diversity in the early fecal microbiota of infants with atopic eczema. J Allergy Clin Immunol. 2008;121(1):129–134. doi:10.1016/j.jaci.2007.09.011.
   PubMed Web of Science ®Google Scholar
• Verhulst SL, Vael C, Beunckens C, Nelen V, Goossens H, Desager K. A longitudinal analysis on the association between antibiotic use, intestinal microflora, and wheezing during the first year of life. J Asthma. 2008; 45(9):828–832. doi:10.1080/02770900802339734.
   PubMed Web of Science ®Google Scholar
• Jia W, Rajani C, Kaddurah-Daouk R, Li H. Expert insights: The potential role of the gut microbiome-bile acid-brain axis in the development and progression of Alzheimer’s disease and hepatic encephalopathy. Medicinal Research Reviews. 2020; 40(4):1496–1507. doi:10.1002/med.21653.
   PubMed Web of Science ®Google Scholar
• Cani PD, Jordan BF. Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. Nat Rev Gastroenterol Hepatol. 2018; 15(11):671–682. doi:10.1038/s41575-018-0025-6.
   PubMed Web of Science ®Google Scholar
• Peled JU, Gomes ALC, Devlin SM, Littmann ER, Taur Y, Sung AD, Weber D, Hashimoto D, Slingerland AE, Slingerland JB. et al. Microbiota as predictor of mortality in allogeneic hematopoietic-cell transplantation. N Engl J Med. 2020;382(9):822–834. doi:10.1056/NEJMoa1900623.
   PubMed Web of Science ®Google Scholar
• Schluter J, Peled JU, Taylor BP, Markey KA, Smith M, Taur Y, Niehus R, Staffas A, Dai A, Fontana E. et al. The gut microbiota is associated with immune cell dynamics in humans. Nature. 2020;588(7837):303–307. doi:10.1038/s41586-020-2971-8.
   PubMed Web of Science ®Google Scholar
• Mager LF, Burkhard R, Pett N, Cooke NCA, Brown K, Ramay H, Paik S, Stagg J, Groves RA, Gallo M. et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science. 2020;369(6510):1481–1489. doi:10.1126/science.abc3421.
   PubMed Web of Science ®Google Scholar
• Li Y, Tinoco R, Elmén L, Segota I, Xian Y, Fujita Y, Sahu A, Zarecki R, Marie K, Feng Y. et al. Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5−/− mice. Nat Commun. 2019;10(1):1492. doi:10.1038/s41467-019-09525-y.
   PubMedGoogle Scholar
• Cheng Y, Liu J, Ling Z. Short-chain fatty acids-producing probiotics: A novel source of psychobiotics. Crit Rev Food Sci Nutr. 2022;62:7929–7959. doi:10.1080/10408398.2021.1920884.
   PubMed Web of Science ®Google Scholar
• Nagpal R, Wang S, Ahmadi S, Hayes J, Gagliano J, Subashchandrabose S, Kitzman DW, Becton T, Read R, Yadav H. Human-origin probiotic cocktail increases short-chain fatty acid production via modulation of mice and human gut microbiome. Sci Rep. 2018; 8(1):12649. doi:10.1038/s41598-018-30114-4.
   PubMedGoogle Scholar
• Seth A, Yan F, Polk DB, Rao R. Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC-and MAP kinase-dependent mechanism. Am J Physiol. 2008; 294(4):1060–1069. doi:10.1152/ajpgi.00202.2007.
   PubMed Web of Science ®Google Scholar
• Tiwari SK, Tiwari SK. Bacteriocin-producing probiotic lactic acid bacteria in controlling dysbiosis of the gut microbiota. Front Cell Infect Microbiol. 2022;12:851140. doi:10.3389/fcimb.2022.851140/full.
   PubMed Web of Science ®Google Scholar
• Li H-Y, Zhou D-D, Gan R-Y, Huang S-Y, Zhao C-N, Shang A, Xu X-Y, Li H-B. Effects and mechanisms of probiotics, prebiotics, synbiotics, and postbiotics on metabolic diseases targeting gut microbiota: A narrative review. Nutrients. 2021; 13(9):3211. doi:10.3390/nu13093211.
   PubMed Web of Science ®Google Scholar
• Madsen KL. The use of probiotics in gastrointestinal disease. Can J Gastroenterol Hepatol. 2001;15:817–822. doi:10.1155/2001/690741.
   Web of Science ®Google Scholar
• Sullivan Å, Nord C. Probiotics and gastrointestinal diseases. J Intern Med. 2005; 257(1):78–92. doi:10.1111/j.1365-2796.2004.01410.x.
   PubMed Web of Science ®Google Scholar
• Aggarwal J, Swami G, Kumar M. Probiotics and their effects on metabolic diseases: an update. J Clin Diagn Res. 2013; 7(1):173–177. doi:10.7860/JCDR/2012/5004.2701.
   PubMedGoogle Scholar
• Huo D, Cen C, Chang H, Ou Q, Jiang S, Pan Y, Chen K, Zhang J. Probiotic Bifidobacterium longum supplied with methimazole improved the thyroid function of Graves’ disease patients through the gut-thyroid axis. Commun Biol. 2021; 4(1):1046. doi:10.1038/s42003-021-02587-z.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Li J, Jiang S, Xu M, Ma T, Sun Z, Zhang J. Lactobacillus fermentum HNU312 alleviated oxidative damage and behavioural abnormalities during brain development in early life induced by chronic lead exposure. Ecotox Environ Safe. 2023;251:114543. doi:10.1016/j.ecoenv.2023.114543.
   PubMed Web of Science ®Google Scholar
• Ebel B, Lemetais G, Beney L, Cachon R, Sokol H, Langella P, Gervais P. Impact of probiotics on risk factors for cardiovascular diseases. A review. Crit Rev Food Sci Nutr. 2014; 54(2):175–189. doi:10.1080/10408398.2011.579361.
   PubMed Web of Science ®Google Scholar
• Ascher S, Reinhardt C. The gut microbiota: an emerging risk factor for cardiovascular and cerebrovascular disease. Eur J Immunol. 2018; 48(4):564–575. doi:10.1002/eji.201646879.
   PubMed Web of Science ®Google Scholar
• Queen J, Shaikh F, Sears CL. Understanding the mechanisms and translational implications of the microbiome for cancer therapy innovation. Nat Cancer. 2023;1–12. doi:10.1038/s43018-023-00602-2.
   PubMedGoogle Scholar
• Tlaskalová-Hogenová H, Štěpánková R, Kozáková H, Hudcovic T, Vannucci L, Tučková L, Rossmann P, Hrnčíř T, Kverka M, Zákostelská Z. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol. 2011; 8(2):110–120. doi:10.1038/cmi.2010.67.
   PubMed Web of Science ®Google Scholar
• Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017; 67(4):326–344. doi:10.3322/caac.21398.
   PubMed Web of Science ®Google Scholar
• Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas M-E. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016; 8(1):1–12. doi:10.1186/S13073-016-0303-2.
   PubMedGoogle Scholar
• Zhang J, Lacroix C, Wortmann E, Ruscheweyh H-J, Sunagawa S, Sturla SJ, Schwab C. Gut microbial beta-glucuronidase and glycerol/diol dehydratase activity contribute to dietary heterocyclic amine biotransformation. BMC Microbiol. 2019; 19(1):1–14. doi:10.1186/s12866-019-1483-x.
   PubMedGoogle Scholar
• Lefort ÉC, Blay J. Apigenin and its impact on gastrointestinal cancers. Mol Nutr Food Res. 2013; 57(1):126–144. doi:10.1002/mnfr.201200424.
   PubMed Web of Science ®Google Scholar
• Polk DB, Peek RM Jr. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer. 2010; 10(6):403–414. doi:10.1038/nrc2857.
   PubMed Web of Science ®Google Scholar
• Talarico S, Leverich CK, Wei B, Ma J, Cao X, Guo Y, Han G, Yao L, Self S, Zhao Y. et al. Increased H. pylori stool shedding and EPIYA-D cagA alleles are associated with gastric cancer in an East Asian hospital. PloS One. 2018;13(9):e0202925. doi:10.1371/journal.pone.0202925.
   PubMed Web of Science ®Google Scholar
• Liang W, Yang Y, Wang H, Wang H, Yu X, Lu Y, Shen S, Teng L. Gut microbiota shifts in patients with gastric cancer in perioperative period. Medicine (Baltimore). 2019; 98(35):e16626. doi:10.1097/MD.0000000000016626.
   PubMed Web of Science ®Google Scholar
• Y-F Q, J-N S, L-F R, X-L C, J-H D, Tao K, X-M G, Y-N C, Su W. Intestinal microbiota is altered in patients with gastric cancer from Shanxi Province, China. Dig Dis Sci. 2019; 64(5):1193–1203. doi:10.1007/s10620-018-5411-y.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhang C, Xu S, Xiang C, Wang R, Yang D, Lu B, Shi L, Tong R, Teng Y. et al. Fecal microbiome alteration may be a potential marker for gastric cancer. Dis Markers. 2020;2020:3461315. doi:10.1155/2020/3461315.
   PubMed Web of Science ®Google Scholar
• Zheng C, Chen T, Wang Y, Gao Y, Kong Y, Liu Z, Deng X. A randomised trial of probiotics to reduce severity of physiological and microbial disorders induced by partial gastrectomy for patients with gastric cancer. J Cancer. 2019; 10(3):568. doi:10.7150/jca.29072.
   PubMed Web of Science ®Google Scholar
• Sarhadi V, Mathew B, Kokkola A, Karla T, Tikkanen M, Rautelin H, Lahti L, Puolakkainen P, Knuutila S. Gut microbiota of patients with different subtypes of gastric cancer and gastrointestinal stromal tumors. Gut Pathog. 2021; 13(1):11. doi:10.1186/s13099-021-00403-x.
   PubMed Web of Science ®Google Scholar
• Feng Q, Liang S, Jia H, Stadlmayr A, Tang L, Lan Z, Zhang D, Xia H, Xu X, Jie Z. et al. Gut microbiome development along the colorectal adenoma–carcinoma sequence. Nat Commun. 2015;6(1):6528. doi:10.1038/ncomms7528.
   PubMed Web of Science ®Google Scholar
• Yu J, Feng Q, Wong SH, Zhang D, Liang QY, Qin Y, Tang L, Zhao H, Stenvang J, Li Y. et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66(1):70–78. doi:10.1136/gutjnl-2015-309800.
   PubMed Web of Science ®Google Scholar
• Boleij A, Hechenbleikner EM, Goodwin AC, Badani R, Stein EM, Lazarev MG, Ellis B, Carroll KC, Albesiano E, Wick EC. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis. 2015; 60(2):208–215. doi:10.1093/cid/ciu787.
   PubMed Web of Science ®Google Scholar
• Huycke MM, Abrams V, Moore DR. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell DNA. Carcinogenesis. 2002; 23(3):529–536. doi:10.1093/carcin/23.3.529.
   PubMed Web of Science ®Google Scholar
• Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, Campbell BJ, Abujamel T, Dogan B, Rogers AB. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012; 338(6103):120–123. doi:10.1126/science.1224820.
   PubMed Web of Science ®Google Scholar
• Boleij A, Tjalsma H. The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease. Lancet Infect Dis. 2013; 13(8):719–724. doi:10.1016/S1473-3099(13)70107-5.
   PubMed Web of Science ®Google Scholar
• Keenan JI, Aitchison A, Purcell RV, Greenlees R, Pearson JF, Frizelle FA. Screening for enterotoxigenic Bacteroides fragilis in stool samples. Anaerobe. 2016;40:50–53. doi:10.1016/j.anaerobe.2016.05.004.
   PubMed Web of Science ®Google Scholar
• Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, Fleck JS, Voigt AY, Palleja A, Ponnudurai R. et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med. 2019;25(4):679–689. doi:10.1038/s41591-019-0406-6.
   PubMed Web of Science ®Google Scholar
• Yachida S, Mizutani S, Shiroma H, Shiba S, Nakajima T, Sakamoto T, Watanabe H, Masuda K, Nishimoto Y, Kubo M. et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med. 2019;25(6):968–976. doi:10.1038/s41591-019-0458-7.
   PubMed Web of Science ®Google Scholar
• Thomas AM, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M, Beghini F, Manara S, Karcher N, Pozzi C. et al. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat Med. 2019;25(4):667–678. doi:10.1038/s41591-019-0405-7.
   PubMed Web of Science ®Google Scholar
• Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019; 16(11):690–704. doi:10.1038/s41575-019-0209-8.
   PubMed Web of Science ®Google Scholar
• Fang W-J, Jing D-Z, Luo Y, Fu C-Y, Zhao P, Qian J, Tian B-R, Chen X-G, Zheng Y-L, Zheng Y. et al. Clostridium difficile carriage in hospitalized cancer patients: a prospective investigation in eastern China. BMC Infect Dis. 2014;14(1):523. doi:10.1186/1471-2334-14-523.
   PubMedGoogle Scholar
• Cheng Y, Ling Z, Li L. The intestinal microbiota and colorectal cancer. Front Immunol. 2020;11:615056. doi:10.3389/fimmu.2020.615056.
   PubMed Web of Science ®Google Scholar
• Deng Y, Tang D, Hou P, Shen W, Li H, Wang T, Liu R. Dysbiosis of gut microbiota in patients with esophageal cancer. Microb Pathog. 2021;150:104709. doi:10.1016/j.micpath.2020.104709.
   PubMed Web of Science ®Google Scholar
• Yang W, Chen C-H, Jia M, Xing X, Gao L, Tsai H-T, Zhang Z, Liu Z, Zeng B, Yeung S-C. Tumor-associated microbiota in esophageal squamous cell carcinoma. Front Cell Dev Biol. 2021;9:641270. doi:10.3389/fcell.2021.641270.
   PubMed Web of Science ®Google Scholar
• Inoue T, Nakayama J, Moriya K, Kawaratani H, Momoda R, Ito K, Iio E, Nojiri S, Fujiwara K, Yoneda M. Gut dysbiosis associated with hepatitis C virus infection. Clin Infect Dis. 2018; 67(6):869–877. doi:10.1093/cid/ciy205.
   PubMed Web of Science ®Google Scholar
• Zhang X, Coker OO, Chu ES, Fu K, Lau HC, Wang Y-X, Chan AW, Wei H, Yang X, Sung JJ. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut. 2021; 70(4):761–774. doi:10.1136/gutjnl-2019-319664.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang D, Qiao S, Wu X, Cao S, Wang L, Su X, Li L. Metabolic and microbial signatures in rat hepatocellular carcinoma treated with caffeic acid and chlorogenic acid. Sci Rep. 2017; 7(1):4508. doi:10.1038/s41598-017-04888-y.
   PubMedGoogle Scholar
• Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1):6. doi:10.1038/s41572-020-00240-3.
   PubMed Web of Science ®Google Scholar
• Ma J, Li J, Jin C, Yang J, Zheng C, Chen K, Xie Y, Yang Y, Bo Z, Wang J. et al. Association of gut microbiome and primary liver cancer: A two‐sample Mendelian randomization and case–control study. Liver Int. 2023; 43(1):221–233. doi:10.1111/liv.15466.
   PubMed Web of Science ®Google Scholar
• Ren Z, Li A, Jiang J, Zhou L, Yu Z, Lu H, Xie H, Chen X, Shao L, Zhang R. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019; 68(6):1014–1023. doi:10.1136/gutjnl-2017-315084.
   PubMed Web of Science ®Google Scholar
• Iida N, Mizukoshi E, Yamashita T, Yutani M, Seishima J, Wang Z, Arai K, Okada H, Yamashita T, Sakai Y. Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis. Nat Cancer. 2021; 2(10):1039–1054. doi:10.1038/s43018-021-00251-3.
   PubMedGoogle Scholar
• Jia X, Lu S, Zeng Z, Liu Q, Dong Z, Chen Y, Zhu Z, Hong Z, Zhang T, Du G. et al. Characterization of gut microbiota, bile acid metabolism, and cytokines in intrahepatic cholangiocarcinoma. Hepatology. 2020;71(3):893–906. doi:10.1002/hep.30852.
   PubMed Web of Science ®Google Scholar
• Ma J, Li J, Jin C, Yang J, Zheng C, Chen K, Xie Y, Yang Y, Bo Z, Wang J. et al. Association of gut microbiome and primary liver cancer: A two-sample Mendelian randomization and case–control study. Liver Int. 2023;43(1):221–233. doi:10.1111/liv.15466.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang S, Jin C, Lin Z, Deng T, Xie X, Deng L, Li X, Ma J, Ding X. A predictive model based on the gut microbiota improves the diagnostic effect in patients with cholangiocarcinoma. Front Cell Infect Microbiol. 2021;2021:1157. doi:10.3389/fcimb.2021.751795/full.
   Google Scholar
• Saab M, Mestivier D, Sohrabi M, Rodriguez C, Khonsari MR, Faraji A, Sobhani I, Dudeja P. Characterization of biliary microbiota dysbiosis in extrahepatic cholangiocarcinoma. PloS One. 2021; 16(3):e0247798. doi:10.1371/journal.pone.0247798.
   PubMed Web of Science ®Google Scholar
• Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E, Mishra A, Mohan N, Aykut B, Usyk M, Torres LE. et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018; 8(4):403–416. doi:10.1158/2159-8290.CD-17-1134.
   PubMed Web of Science ®Google Scholar
• Kartal E, Schmidt TS, Molina-Montes E, Rodríguez-Perales S, Wirbel J, Maistrenko OM, Akanni WA, Alhamwe BA, Alves RJ, Carrato A. A faecal microbiota signature with high specificity for pancreatic cancer. Gut. 2022; 71(7):1359–1372. doi:10.1136/gutjnl-2021-324755.
   PubMed Web of Science ®Google Scholar
• Nagata N, Nishijima S, Kojima Y, Hisada Y, Imbe K, Miyoshi-Akiyama T, Suda W, Kimura M, Aoki R, Sekine K. Metagenomic identification of microbial signatures predicting pancreatic cancer from a multinational study. Gastroenterology. 2022; 163(1):222–238. doi:10.1053/j.gastro.2022.03.054.
   PubMed Web of Science ®Google Scholar
• Bard JM, Luu HT, Dravet F, Michel C, Moyon T, Pagniez A, Nazih H, Bobin-Dubigeon C. Relationship between intestinal microbiota and clinical characteristics of patients with early stage breast cancer. Faseb J. 2015;29:914. doi:10.1096/fasebj.29.1_supplement.914.2.
   Web of Science ®Google Scholar
• Thu MS, Chotirosniramit K, Nopsopon T, Hirankarn N, Pongpirul K. Human gut, breast, and oral microbiome in breast cancer: A systematic review and meta-analysis. Front Oncol. 2023;13:1144021. doi:10.3389/fonc.2023.1144021.
   PubMedGoogle Scholar
• Minelli EB, Beghini A, Vesentini S, Marchiori L, Nardo G, Cerutti R, Mortani E. Intestinal microflora as an alternative metabolic source of estrogens in women with uterine leiomyoma and breast cancer. Ann N Y Acad Sci. 1990; 595(1):473–479. doi:10.1111/j.1749-6632.1990.tb34337.x.
   Google Scholar
• Zhu J, Liao M, Yao Z, Liang W, Li Q, Liu J, Yang H, Ji Y, Wei W, Tan A. et al. Breast cancer in postmenopausal women is associated with an altered gut metagenome. Microbiome. 2018;6(1):136. doi:10.1186/s40168-018-0515-3.
   PubMed Web of Science ®Google Scholar
• Goedert JJ, Jones G, Hua X, Xu X, Yu G, Flores R, Falk RT, Gail MH, Shi J, Ravel J. et al. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J Natl Cancer Inst. 2015;107:147. doi:10.1093/jnci/djv147.
   Google Scholar
• Fuhrman BJ, Feigelson HS, Flores R, Gail MH, Xu X, Ravel J, Goedert JJ. Associations of the fecal microbiome with urinary estrogens and estrogen metabolites in postmenopausal women. J Clin Endocrinol Metab. 2014;99:4632–4640. doi:10.1210/jc.2014-2222.
   PubMed Web of Science ®Google Scholar
• Yamamoto ML, Maier I, Dang AT, Berry D, Liu J, Ruegger PM, Yang JI, Soto PA, Presley LL, Reliene R. et al. Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity. Cancer Res. 2013;73:4222–4232. doi:10.1158/0008-5472.CAN-13-0022.
   PubMed Web of Science ®Google Scholar
• Zhuang H, Cheng L, Wang Y, Zhang Y, Zhao M, Liang G, Zhang M, Li Y, Zhao J, Gao Y. Dysbiosis of the gut microbiome in lung cancer. Front Cell Infect Microbiol. 2019;9:112. doi:10.3389/fcimb.2019.00112.
   PubMed Web of Science ®Google Scholar
• Zhang W-Q, Zhao S-K, Luo J-W, Dong X-P, Hao Y-T, Li H, Shan L, Zhou Y, Shi H-B, Zhang Z-Y. Alterations of fecal bacterial communities in patients with lung cancer. Am J Transl Res. 2018; 10(10):3171. doi: AJTR0077798.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Fang Z, Xue Y, Zhang J, Zhu J, Gao R, Yao S, Ye Y, Wang S, Lin C. Specific gut microbiome signature predicts the early-stage lung cancer. Gut Microbes. 2020; 11(4):1030–1042. doi:10.1080/19490976.2020.1737487.
   PubMed Web of Science ®Google Scholar
• Han W, Wang N, Han M, Liu X, Sun T, Xu J. Identification of microbial markers associated with lung cancer based on multi‐cohort 16 s rRNA analyses: A systematic review and meta‐analysis. Cancer Med. 2023; 12(18):19301–19319. doi:10.1002/cam4.6503.
   PubMed Web of Science ®Google Scholar
• Zhang WQ, Zhao SK, Luo JW, Dong XP, Hao YT, Li H, Shan L, Zhou Y, Shi HB, Zhang ZY. et al. Alterations of fecal bacterial communities in patients with lung cancer. Am J Transl Res. 2018;10(10):3171–3185.
   PubMed Web of Science ®Google Scholar
• Botticelli A, Putignani L, Zizzari I, Del Chierico F, Reddel S, Di Pietro F, Quagliarello A, Onesti CE, Raffaele G, Mazzuca F. Changes of microbiome profile during nivolumab treatment in NSCLC patients. J Clin Oncol. 2018;36:e15020. doi:10.1200/JCO.2018.36.15_suppl.e15020.
   Google Scholar
• Gui Q, Li H, Wang A, Zhao X, Tan Z, Chen L, Xu K, Xiao C. The association between gut butyrate‐producing bacteria and non‐small‐cell lung cancer. J Clin Lab Anal. 2020;34:e23318. doi:10.1002/jcla.23318.
   PubMed Web of Science ®Google Scholar
• Golombos DM, Ayangbesan A, O’Malley P, Lewicki P, Barlow L, Barbieri CE, Chan C, DuLong C, Abu-Ali G, Huttenhower C. et al. The role of gut microbiome in the pathogenesis of prostate cancer: a prospective, pilot study. Urology. 2018;111:122–128. doi:10.1016/j.urology.2017.08.039.
   PubMed Web of Science ®Google Scholar
• Popović V B, M Š, Chow C-E, Chan LS, Roje B, Terzić J. The urinary microbiome associated with bladder cancer. Sci Rep. 2018; 8(1):12157. doi:10.1038/s41598-018-29054-w.
   PubMedGoogle Scholar
• Wu P, Zhang G, Zhao J, Chen J, Chen Y, Huang W, Zhong J, Zeng J. Profiling the urinary microbiota in male patients with bladder cancer in China. Front Cell Infect Microbiol. 2018;8:167. doi:10.3389/fcimb.2018.00167.
   PubMed Web of Science ®Google Scholar
• He C, Li B, Huang L, Teng C, Bao Y, Ren M, Shan Y. Gut microbial composition changes in bladder cancer patients: A case-control study in Harbin, China. Asia Pac J Clin Nutr. 2020; 29(2):395–403. doi:10.6133/apjcn.202007_29(2).0022.
   PubMed Web of Science ®Google Scholar
• Hu X, Xu X, Zeng X, Jin R, Wang S, Jiang H, Tang Y, Chen G, Wei J, Chen T. Gut microbiota dysbiosis promotes the development of epithelial ovarian cancer via regulating Hedgehog signaling pathway. Gut Microbes. 2023; 15(1):2221093. doi:10.1080/19490976.2023.2221093.
   PubMed Web of Science ®Google Scholar
• Wang Z, Qin X, Hu D, Huang J, Guo E, Xiao R, Li W, Sun C, Chen G. Akkermansia supplementation reverses the tumor-promoting effect of the fecal microbiota transplantation in ovarian cancer. Cell Rep. 2022; 41(13):41. doi:10.1016/j.celrep.2022.111890.
   Web of Science ®Google Scholar
• Kang G-U, Jung D-R, Lee YH, Jeon SY, Han HS, Chong GO, Shin J-H. Dynamics of Fecal microbiota with and without invasive cervical cancer and its application in early diagnosis. Cancers. 2020; 12(12):3800. doi:10.3390/cancers12123800.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang Q, Zhao J, Gong L, Zhang Y, Wang X, Yuan Z. Altered diversity and composition of the gut microbiome in patients with cervical cancer. AMB Express. 2019; 9(1):1–9. doi:10.1186/s13568-019-0763-z.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023; 73(3):233–254. doi:10.3322/caac.21772.
   PubMed Web of Science ®Google Scholar
• Quaglio AEV, Grillo TG, De Oliveira ECS, Di Stasi LC, Sassaki LY. Gut microbiota, inflammatory bowel disease and colorectal cancer. World J Gastroenterol. 2022; 28(30):4053–4060. doi:10.3748/wjg.v28.i30.4053.
   PubMed Web of Science ®Google Scholar
• Wu S, Rhee K-J, Albesiano E, Rabizadeh S, Wu X, Yen H-R, Huso DL, Brancati FL, Wick E, McAllister F. et al. A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med. 2009;15(9):1016–1022. doi:10.1038/nm.2015.
   PubMed Web of Science ®Google Scholar
• Brennan CA, Garrett WS. Gut microbiota, inflammation, and colorectal cancer. Annu Rev Microbiol. 2016; 70(1):395–411. doi:10.1146/annurev-micro-102215-095513.
   PubMedGoogle Scholar
• Li S, Konstantinov SR, Smits R, Peppelenbosch MP. Bacterial biofilms in colorectal cancer initiation and progression. Trends Mol Med. 2017; 23(1):18–30. doi:10.1016/j.molmed.2016.11.004.
   PubMed Web of Science ®Google Scholar
• Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015; 13(5):269–284. doi:10.1038/nrmicro3432.
   PubMed Web of Science ®Google Scholar
• Wilson MR, Jiang Y, Villalta PW, Stornetta A, Boudreau PD, Carrá A, Brennan CA, Chun E, Ngo L, Samson LD. The human gut bacterial genotoxin colibactin alkylates DNA. Science. 2019; 363(6428):eaar7785. doi:10.1126/science.aar7785.
   PubMed Web of Science ®Google Scholar
• Foegeding NJ, Jones ZS, Byndloss MX. Western lifestyle as a driver of dysbiosis in colorectal cancer. Dis Model Mech. 2021; 14(5):14. doi:10.1242/dmm.049051.
   Web of Science ®Google Scholar
• Tsoi H, Chu ES, Zhang X, Sheng J, Nakatsu G, Ng SC, Chan AW, Chan FK, Sung JJ, Yu J. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice. Gastroenterology. 2017; 152(6):1419–1433.e5. doi:10.1053/j.gastro.2017.01.009.
   PubMed Web of Science ®Google Scholar
• Dai Z, Coker OO, Nakatsu G, WKK W, Zhao L, Chen Z, Chan FKL, Kristiansen K, Sung JJY, Wong SH. Multi-cohort analysis of colorectal cancer metagenome identified altered bacteria across populations and universal bacterial markers. Microbiome. 2018; 6(1):70. doi:10.1186/s40168-018-0451-2.
   PubMed Web of Science ®Google Scholar
• Ma C, Chen K, Wang Y, Cen C, Zhai Q, Zhang J. Establishing a novel colorectal cancer predictive model based on unique gut microbial single nucleotide variant markers. Gut Microbes. 2020; 13(1):1–6. doi:10.1080/19490976.2020.1869505.
   Web of Science ®Google Scholar
• Dixon WG, Solomon DH. Bisphosphonates and esophageal cancer—a pathway through the confusion. Nat Rev Rheumatol. 2011; 7(6):369–372. doi:10.1038/nrrheum.2011.60.
   PubMed Web of Science ®Google Scholar
• Park H, Clark E, Cullen JJ, Koland JG, Kim MS, Conklin JL. Expression of inducible nitric oxide synthase in the lower esophageal sphincter of the endotoxemic opossum. J Gastroenterolo. 2002; 37(12):1000–1004. doi:10.1007/s005350200169.
   PubMed Web of Science ®Google Scholar
• Petrick JL, Florio AA, Koshiol J, Pfeiffer RM, Yang B, Yu K, Chen CJ, Yang HI, Lee MH, McGlynn KA. Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies. Int J Cancer. 2020; 147(10):2743–2753. doi:10.1002/ijc.33051.
   PubMed Web of Science ®Google Scholar
• McBrearty N, Arzumanyan A, Bichenkov E, Merali S, Merali C, Feitelson M. Short chain fatty acids delay the development of hepatocellular carcinoma in HBx transgenic mice. Neoplasia. 2021; 23(5):529–538. doi:10.1016/j.neo.2021.04.004.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs LP, Ma L, Roy S, Fu Q, Brown ZJ. et al. Gut microbiome directs hepatocytes to recruit MDSC and promote cholangiocarcinoma. Cancer Discov. 2020;11(5):1248–1267. doi:10.1158/2159-8290.CD-20-0304.
   PubMed Web of Science ®Google Scholar
• Ponziani FR, De Luca A, Picca A, Marzetti E, Petito V, Del Chierico F, Reddel S, Paroni Sterbini F, Sanguinetti M, Putignani L. Gut dysbiosis and fecal calprotectin predict response to immune checkpoint inhibitors in patients with hepatocellular carcinoma. Hepatol Commun. 2022; 6(6):1492–1501. doi:10.1002/hep4.1905.
   PubMed Web of Science ®Google Scholar
• Deng T, Li J, He B, Chen B, Liu F, Chen Z, Zheng J, Shi Z, Zhang T, Deng L. Gut microbiome alteration as a diagnostic tool and associated with inflammatory response marker in primary liver cancer. Hepatol Int. 2022; 16(1):99–111. doi:10.1007/s12072-021-10279-3.
   PubMed Web of Science ®Google Scholar
• Sethi V, Vitiello GA, Saxena D, Miller G, Dudeja V. The role of the microbiome in immunologic development and its implication for pancreatic cancer immunotherapy. Gastroenterology. 2019; 156(7):2097–2115. doi:10.1053/j.gastro.2018.12.045.
   PubMed Web of Science ®Google Scholar
• Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004;96:1856–1865. doi:10.1093/jnci/djh336.
   PubMed Web of Science ®Google Scholar
• Muti P, Bradlow HL, Micheli A, Krogh V, Freudenheim JL, Schunemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M. et al. Estrogen Metabolism and Risk of Breast Cancer: A Prospective Study of the 2: 16α-Hydroxyestrone Ratio in Premenopausal and Postmenopausal Women. Epidemiology. 2000;11(6):635–640. doi:10.1097/00001648-200011000-00004.
   PubMed Web of Science ®Google Scholar
• Hill MJ, Goddard P, Williams REO. GUT BACTERIA and ÆTIOLOGY of CANCER of the BREAST. Lancet. 1971; 298(7722):472–473. doi:10.1016/S0140-6736(71)92634-1.
   Google Scholar
• Laborda-Illanes A, Sanchez-Alcoholado L, Dominguez-Recio ME, Jimenez-Rodriguez B, Lavado R, Comino-Mendez I, Alba E, Queipo-Ortuno MI. Breast and gut microbiota action mechanisms in breast cancer pathogenesis and treatment. Cancers. 2020; 12(9):2465. doi:10.3390/cancers12092465.
   PubMed Web of Science ®Google Scholar
• Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA, Spicer D. Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study. Breast Cancer Res Treat. 2020; 182(2):451–463. doi:10.1007/s10549-020-05702-6.
   PubMed Web of Science ®Google Scholar
• Halbrook CJ, Lyssiotis CA, Pasca di Magliano, di Magliano MP A, Pasca di Magliano M. Pancreatic cancer: Advances and challenges. Cell. 2023; 186(8):1729–1754. doi:10.1016/j.cell.2023.02.014.
   PubMed Web of Science ®Google Scholar
• Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A. Tumor microbiome diversity and composition influence pancreatic cancer outcomes. Cell. 2019; 178(4):795–806. e12. doi:10.1016/j.cell.2019.07.008.
   PubMed Web of Science ®Google Scholar
• Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet. 2014;384:691–702. doi:10.1016/S0140-6736(14)61136-3.
   PubMed Web of Science ®Google Scholar
• Sommariva M, Le Noci V, Bianchi F, Camelliti S, Balsari A, Tagliabue E, Sfondrini L. The lung microbiota: role in maintaining pulmonary immune homeostasis and its implications in cancer development and therapy. Cell Mol Life Sci. 2020; 77(14):2739–2749. doi:10.1007/s00018-020-03452-8.
   PubMed Web of Science ®Google Scholar
• Yu G, Gail MH, Consonni D, Carugno M, Humphrys M, Pesatori AC, Caporaso NE, Goedert JJ, Ravel J, Landi MT. Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features. Genome Biol. 2016; 17(1):1–12. doi:10.1186/s13059-016-1021-1.
   PubMedGoogle Scholar
• Hoste E, Arwert EN, Lal R, South AP, Salas-Alanis JC, Murrell DF, Donati G, Watt FM. Innate sensing of microbial products promotes wound-induced skin cancer. Nat Commun. 2015; 6(1):5932. doi:10.1038/ncomms6932.
   PubMedGoogle Scholar
• Wong-Rolle A, Wei HK, Zhao C, Jin C. Unexpected guests in the tumor microenvironment: microbiome in cancer. Protein Cell. 2021; 12(5):426–435. doi:10.1007/s13238-020-00813-8.
   PubMed Web of Science ®Google Scholar
• Jin C, Lagoudas GK, Zhao C, Bullman S, Bhutkar A, Hu B, Ameh S, Sandel D, Liang XS, Mazzilli S. Commensal microbiota promote lung cancer development via γδ T cells. Cell. 2019; 176(5):998–1013. doi:10.1016/j.cell.2018.12.040.
   PubMed Web of Science ®Google Scholar
• Yang L, Li A, Wang Y, Zhang Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct Target Ther. 2023; 8(1):35. doi:10.1038/s41392-022-01304-4.
   PubMed Web of Science ®Google Scholar
• Nejman D, Livyatan I, Fuks G, Gavert N, Zwang Y, Geller LT, Rotter-Maskowitz A, Weiser R, Mallel G, Gigi E. The human tumor microbiome is composed of tumor type–specific intracellular bacteria. Science. 2020; 368(6494):973–980. doi:10.1126/science.aay9189.
   PubMed Web of Science ®Google Scholar
• Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, Kosciolek T, Janssen S, Metcalf J, Song SJ. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020; 579(7800):567–574. doi:10.1038/s41586-020-2095-1.
   PubMed Web of Science ®Google Scholar
• Greathouse KL, Stone JK, Harris CC. Cancer-type-specific bacteria: freeloaders or partners? Cancer Cell. 2020; 38(2):158–160. doi:10.1016/j.ccell.2020.06.017.
   PubMed Web of Science ®Google Scholar
• Luan C, Xie L, Yang X, Miao H, Lv N, Zhang R, Xiao X, Hu Y, Liu Y, Wu N. Dysbiosis of fungal microbiota in the intestinal mucosa of patients with colorectal adenomas. Sci Rep. 2015; 5(1):7980. doi:10.1038/srep07980.
   PubMedGoogle Scholar
• Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, Wu X, Shields CE D, Hechenbleikner EM, Huso DL. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 2018; 359(6375):592–597. doi:10.1126/science.aah3648.
   PubMed Web of Science ®Google Scholar
• Buc E, Dubois D, Sauvanet P, Raisch J, Delmas J, Darfeuille-Michaud A, Pezet D, Bonnet R, Battista JR. High prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon cancer. PloS One. 2013; 8(2):e56964. doi:10.1371/journal.pone.0056964.
   PubMed Web of Science ®Google Scholar
• Arthur JC. Microbiota and colorectal cancer: colibactin makes its mark. Nat Rev Gastroenterol Hepatol. 2020; 17(6):317–318. doi:10.1038/s41575-020-0303-y.
   PubMed Web of Science ®Google Scholar
• Laroumagne S, Lepage B, Hermant C, Plat G, Phelippeau M, Bigay-Game L, Lozano S, Guibert N, Segonds C, Mallard V. Bronchial colonisation in patients with lung cancer: a prospective study. Eur Respir J. 2013; 42(1):220–229. doi:10.1183/09031936.00062212.
   PubMed Web of Science ®Google Scholar
• Lee SH, Sung JY, Yong D, Chun J, Kim SY, Song JH, Chung KS, Kim EY, Jung JY, Kang YA. Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. Lung Cancer. 2016;102:89–95. doi:10.1016/j.lungcan.2016.10.016.
   PubMed Web of Science ®Google Scholar
• Cameron SJ, Lewis KE, Huws SA, Hegarty MJ, Lewis PD, Pachebat JA, Mur LA, Guo NL. A pilot study using metagenomic sequencing of the sputum microbiome suggests potential bacterial biomarkers for lung cancer. PloS One. 2017; 12(5):e0177062. doi:10.1371/journal.pone.0177062.
   PubMed Web of Science ®Google Scholar
• Tsay J-C, Wu BG, Badri MH, Clemente JC, Shen N, Meyn P, Li Y, Yie T-A, Lhakhang T, Olsen E. Airway microbiota is associated with upregulation of the PI3K pathway in lung cancer. Am J Respir Crit Care Med. 2018; 198(9):1188–1198. doi:10.1164/rccm.201710-2118OC.
   PubMed Web of Science ®Google Scholar
• Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non–small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019; 37(18):1558. doi:10.1200/JCO.19.00201.
   PubMed Web of Science ®Google Scholar
• Zheng X, Sun X, Liu Q, Huang Y, Yuan Y. The composition alteration of respiratory microbiota in lung cancer. Cancer Invest. 2020;38:158–168. doi:10.1080/07357907.2020.1732405.
   PubMed Web of Science ®Google Scholar
• Han W, Wang N, Han M, Liu X, Sun T, Xu J. Identification of microbial markers associated with lung cancer based on multi-cohort 16 s rRNA analyses: A systematic review and meta-analysis. Cancer Med. 2023; 12(18):19301–19319. doi:10.1002/cam4.6503.
   PubMed Web of Science ®Google Scholar
• Yan X, Yang M, Liu J, Gao R, Hu J, Li J, Zhang L, Shi Y, Guo H, Cheng J. Discovery and validation of potential bacterial biomarkers for lung cancer. Am J Cancer Res. 2015;5:3111. doi: ajcr0009363.
   PubMed Web of Science ®Google Scholar
• Cheng C, Wang Z, Wang J, Ding C, Sun C, Liu P, Xu X, Liu Y, Chen B, Gu B. Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer. Transl Lung Cancer Res. 2020; 9(3):693. doi:10.21037/tlcr-19-590.
   PubMed Web of Science ®Google Scholar
• Greathouse KL, White JR, Vargas AJ, Bliskovsky BJ VV, von Muhlinen N, Polley EC, Bowman ED, Khan MA, Robles AI, Robles AI. Interaction between the microbiome and TP53 in human lung cancer. Genome Biol. 2018; 19(1):1–16. doi:10.1186/s13059-018-1501-6.
   PubMedGoogle Scholar
• Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017; 357(6356):1156–1160. doi:10.1126/science.aah5043.
   PubMed Web of Science ®Google Scholar
• Chai X, Wang J, Li H, Gao C, Li S, Wei C, Huang J, Tian Y, Yuan J, Lu J. Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma. Gut Microbes. 2023; 15(1):2156255. doi:10.1080/19490976.2022.2156255.
   PubMed Web of Science ®Google Scholar
• Segura-López FK, Güitrón-Cantú A, Torres J. Association between Helicobacter spp. infections and hepatobiliary malignancies: a review. World J Gastroenterol. 2015; 21(5):1414–1423. doi:10.3748/wjg.v21.i5.1414.
   PubMed Web of Science ®Google Scholar
• Boonyanugomol W, Chomvarin C, Sripa B, Bhudhisawasdi V, Khuntikeo N, Hahnvajanawong C, Chamsuwan A. Helicobacter pylori in Thai patients with cholangiocarcinoma and its association with biliary inflammation and proliferation. HPB. 2012; 14(3):177–184. doi:10.1111/j.1477-2574.2011.00423.x.
   PubMedGoogle Scholar
• Zhang Q, Ma C, Duan Y, Heinrich B, Rosato U, Diggs LP, Ma L, Roy S, Fu Q, Brown ZJ. et al. Gut microbiome directs hepatocytes to recruit MDSCs and promote cholangiocarcinoma. Cancer Discov. 2021; 11(5):1248–1267. doi:10.1158/2159-8290.CD-17-1134.
   PubMed Web of Science ®Google Scholar
• Xuan C, Shamonki JM, Chung A, ML D, Chung M, Sieling PA, Lee DJ, Takabe K. Microbial dysbiosis is associated with human breast cancer. PloS One. 2014; 9(1):e83744. doi:10.1371/journal.pone.0083744.
   PubMed Web of Science ®Google Scholar
• Thompson KJ, Ingle JN, Tang X, Chia N, Jeraldo PR, Walther-Antonio MR, Kandimalla KK, Johnson S, Yao JZ, Harrington SC. et al. A comprehensive analysis of breast cancer microbiota and host gene expression. PloS One. 2017; 12(11):e0188873. doi:10.1371/journal.pone.0188873.
   PubMed Web of Science ®Google Scholar
• Banerjee S, Tian T, Wei Z, Shih N, Feldman MD, Peck KN, AM D, Alwine JC, Robertson ES. Distinct microbial signatures associated with different breast cancer types. Front Microbiol. 2018;9:951. doi:10.3389/fmicb.2018.00951.
   PubMed Web of Science ®Google Scholar
• Parhi L, Alon-Maimon T, Sol A, Nejman D, Shhadeh A, Fainsod-Levi T, Yajuk O, Isaacson B, Abed J, Maalouf N. Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression. Nat Commun. 2020; 11(1):3259. doi:10.1038/s41467-020-16967-2.
   PubMed Web of Science ®Google Scholar
• Hieken TJ, Chen J, Hoskin TL, Walther-Antonio M, Johnson S, Ramaker S, Xiao J, Radisky DC, Knutson KL, Kalari KR. The microbiome of aseptically collected human breast tissue in benign and malignant disease. Sci Rep. 2016; 6(1):30751. doi:10.1038/srep30751.
   PubMedGoogle Scholar
• Yamamura K, Baba Y, Nakagawa S, Mima K, Miyake K, Nakamura K, Sawayama H, Kinoshita K, Ishimoto T, Iwatsuki M. Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin Cancer Res. 2016;22:5574–5581. doi:10.1158/1078-0432.CCR-16-1786.
   PubMed Web of Science ®Google Scholar
• Parida S, Wu S, Siddharth S, Wang G, Muniraj N, Nagalingam A, Hum C, Mistriotis P, Hao H, Talbot CC Jr. A procarcinogenic colon microbe promotes breast tumorigenesis and metastatic progression and concomitantly activates notch and β-catenin axes. Cancer Discov. 2021;11:1138–1157. doi:10.1158/2159-8290.CD-20-0537.
   PubMed Web of Science ®Google Scholar
• Urbaniak C, Gloor GB, Brackstone M, Scott L, Tangney M, Reid G, Goodrich-Blair H. The microbiota of breast tissue and its association with breast cancer. Appl Environ Microbiol. 2016; 82(16):5039–5048. doi:10.1128/aem.01235-16.
   PubMed Web of Science ®Google Scholar
• Meng S, Chen B, Yang J, Wang J, Zhu D, Meng Q, Zhang L. Study of microbiomes in aseptically collected samples of human breast tissue using needle biopsy and the potential role of in situ tissue microbiomes for promoting malignancy. Front Oncol. 2018;8:318. doi:10.3389/fonc.2018.00318.
   PubMed Web of Science ®Google Scholar
• Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA. et al. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012; 22(2):299–306. doi:10.1101/gr.126516.111.
   PubMed Web of Science ®Google Scholar
• Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J. et al. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res. 2012; 22(2):292–298. doi:10.1101/gr.126573.111.
   PubMed Web of Science ®Google Scholar
• Replication Study RJ, Iorns E, Denis A, Williams SR, Perfito N, Errington TM. Replication Study: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Elife. 2018;7:e25801. doi:10.7554/eLife.25801.
   PubMed Web of Science ®Google Scholar
• Mrázek J, Mekadim C, Kučerová P, Švejstil R, Salmonová H, Vlasáková J, Tarasová R, Čížková J, Červinková M. Melanoma-related changes in skin microbiome. Folia Microbiol. 2019; 64(3):435–442. doi:10.1007/s12223-018-00670-3.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews M, Karpinets T, Prieto P, Vicente D, Hoffman K, Wei SC. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients. Science. 2018; 359(6371):97–103. doi:10.1126/science.aan4236.
   PubMed Web of Science ®Google Scholar
• Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre M-L, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients. Science. 2018; 359(6371):104–108. doi:10.1126/science.aao3290.
   PubMed Web of Science ®Google Scholar
• Routy B, Le Chatelier E, Derosa L, Duong CP, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 2018; 359(6371):91–97. doi:10.1126/science.aan3706.
   PubMed Web of Science ®Google Scholar
• Yang J, He Q, Lu F, Chen K, Ni Z, Wang H, Zhou C, Zhang Y, Chen B, Bo Z. A distinct microbiota signature precedes the clinical diagnosis of hepatocellular carcinoma. Gut Microbes. 2023; 15(1):2201159. doi:10.1080/19490976.2023.2201159.
   PubMed Web of Science ®Google Scholar
• Liu Q, Li F, Zhuang Y, Xu J, Wang J, Mao X, Zhang Y, Liu X. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. Gut Pathog. 2019; 11(1):1–13. doi:10.1186/s13099-018-0281-6.
   PubMedGoogle Scholar
• Sun L, Ke X, Guan A, Jin B, Qu J, Wang Y, Xu X, Li C, Sun H, Xu H. Intratumoural microbiome can predict the prognosis of hepatocellular carcinoma after surgery. Clin Transl Med. 2023; 13(7):e1331. doi:10.1002/ctm2.1331.
   PubMed Web of Science ®Google Scholar
• Qu D, Wang Y, Xia Q, Chang J, Jiang X, Zhang H. Intratumoral microbiome of human primary liver cancer. Hepatol Commun. 2022; 6(7):1741–1752. doi:10.1002/hep4.1908.
   PubMed Web of Science ®Google Scholar
• Liou J-M, Malfertheiner P, Lee Y-C, Sheu B-S, Sugano K, Cheng H-C, Yeoh K-G, Hsu P-I, Goh K-L, Mahachai V. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020; 69(12):2093–2112. doi:10.1136/gutjnl-2020-322368.
   PubMed Web of Science ®Google Scholar
• Baba Y, Hara Y, Toihata T, Kosumi K, Iwatsuki M, Iwagami S, Miyamoto Y, Yoshida N, Komohara Y, Baba H. Relationship between gut microbiome Fusobacterium nucleatum and LINE-1 methylation level in esophageal cancer. Esophagus. 2023; 20(4):704–712. doi:10.1007/s10388-023-01009-9.
   PubMed Web of Science ®Google Scholar
• Salachan PV, Rasmussen M, Fredsøe J, Ulhøi B, Borre M, Sørensen KD. Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling. Genome Med. 2022; 14(1):1–18. doi:10.1186/s13073-022-01011-3.
   PubMed Web of Science ®Google Scholar
• Cohen RJ, Shannon BA, JE M, Shannon T, Garrett KL. Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: a possible link to cancer evolution? J Urol. 2005; 173(6):1969–1974. doi:10.1097/01.ju.0000158161.15277.78.
   PubMed Web of Science ®Google Scholar
• Yow MA, Tabrizi SN, Severi G, Bolton DM, Pedersen J, Giles GG, Southey MC. Characterisation of microbial communities within aggressive prostate cancer tissues. Infect Agent Cancer. 2017; 12(1):1–10. doi:10.1186/s13027-016-0112-7.
   PubMedGoogle Scholar
• Cavarretta I, Ferrarese R, Cazzaniga W, Saita D, Lucianò R, Ceresola ER, Locatelli I, Visconti L, Lavorgna G, Briganti A. The microbiome of the prostate tumor microenvironment. Eur Urol. 2017;72:625–631. doi:10.1016/j.eururo.2017.03.029.
   PubMed Web of Science ®Google Scholar
• Feng Y, Ramnarine VR, Bell R, Volik S, Davicioni E, Hayes VM, Ren S, Collins CC. Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. Bmc Genom. 2019; 20(1):1–8. doi:10.1186/s12864-019-5457-z.
   PubMedGoogle Scholar
• Banerjee S, Alwine JC, Wei Z, Tian T, Shih N, Sperling C, Guzzo T, Feldman MD, Robertson ES. Microbiome signatures in prostate cancer. Carcinogenesis. 2019; 40(6):749–764. doi:10.1093/carcin/bgz008.
   PubMed Web of Science ®Google Scholar
• Zheng D-W, Deng W-W, Song W-F, Wu C-C, Liu J, Hong S, Zhuang Z-N, Cheng H, Sun Z-J, Zhang X-Z. Biomaterial-mediated modulation of oral microbiota synergizes with PD-1 blockade in mice with oral squamous cell carcinoma. Nat Biomed Eng. 2022; 6(1):32–43. doi:10.1038/s41551-021-00807-9.
   PubMed Web of Science ®Google Scholar
• Galeano Niño JL, Wu H, KD L, Kempchinsky AG, Baryiames A, Barber B, Futran N, Houlton J, Sather C, Sicinska E. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature. 2022; 611(7937):810–817. doi:10.1038/s41586-022-05435-0.
   PubMed Web of Science ®Google Scholar
• Erdmann J. How gut bacteria could boost cancer treatments. Nature. 2022; 607(7919):436–439. doi:10.1038/d41586-022-01959-7.
   PubMed Web of Science ®Google Scholar
• Clay SL, Fonseca-Pereira D, Garrett WS. Colorectal cancer: the facts in the case of the microbiota. J Clin Investig. 2022; 132(4):132. doi:10.1172/JCI155101.
   Web of Science ®Google Scholar
• Song M, Garrett WS, Chan AT. Nutrients, foods, and colorectal cancer prevention. Gastroenterology. 2015; 148(6):1244–1260. doi:10.1053/j.gastro.2014.12.035.
   PubMed Web of Science ®Google Scholar
• Vilenchik M, Solit D, Basso A, Huezo H, Lucas B, He H, Rosen N, Spampinato C, Modrich P, Chiosis G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem Biol. 2004;11:787–797. doi:10.1016/j.chembiol.2004.04.008.
   PubMed Web of Science ®Google Scholar
• Sell S. Alpha-fetoprotein, stem cells and cancer: how study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmation of the stem cell theory of cancer. Tumor Biol. 2008;29:161–180. doi:10.1159/000143402.
   PubMedGoogle Scholar
• Secher T, Samba-Louaka A, Oswald E, Nougayrède J-P, Sherman M. Escherichia coli producing colibactin triggers premature and transmissible senescence in mammalian cells. PloS One. 2013; 8(10):e77157. doi:10.1371/journal.pone.0077157.
   PubMed Web of Science ®Google Scholar
• Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wood HM, Nomburg J, Gurjao C, Manders F, Dalmasso G, Stege PB. Mutational signature in colorectal cancer caused by genotoxic pks+. E coli Nat. 2020;580:269–273. doi:10.1038/s41586-020-2080-8.
   PubMed Web of Science ®Google Scholar
• Farge E. Mechanotransduction in development. Curr Top Dev Biol. 2011;95:243–265. doi:10.1016/B978-0-12-385065-2.00008-6.
   PubMed Web of Science ®Google Scholar
• Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/β-catenin signaling via its FadA adhesin. Cell Host & Microbe. 2013; 14(2):195–206. doi:10.1016/j.chom.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Peng C, Ouyang Y, Lu N, Li N. The NF-κB signaling pathway, the microbiota, and gastrointestinal tumorigenesis: recent advances. Front Immunol. 2020;11:1387. doi:10.3389/fimmu.2020.01387.
   PubMed Web of Science ®Google Scholar
• Garajová I, Balsano R, Wang H, Leonardi F, Giovannetti E, Deng D, Peters GJ. The role of the microbiome in drug resistance in gastrointestinal cancers. Expert Rev Anticancer Ther. 2021;21:165–176. doi:10.1080/14737140.2021.1844007.
   PubMed Web of Science ®Google Scholar
• Wei M-Y, Shi S, Liang C, Meng Q-C, Hua J, Zhang Y-Y, Liu J, Zhang B, Xu J, Yu X-J. The microbiota and microbiome in pancreatic cancer: more influential than expected. Mol Cancer. 2019; 18(1):1–15. doi:10.1186/s12943-019-1008-0.
   PubMed Web of Science ®Google Scholar
• Goldszmid RS, Dzutsev A, Trinchieri G. Host immune response to infection and cancer: unexpected commonalities. Cell Host & Microbe. 2014; 15(3):295–305. doi:10.1016/j.chom.2014.02.003.
   PubMed Web of Science ®Google Scholar
• Dai E, Zhu Z, Wahed S, Qu Z, Storkus WJ, Guo ZS. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol Cancer. 2021; 20(1):1–27. doi:10.1186/s12943-021-01464-x.
   PubMed Web of Science ®Google Scholar
• Ray AL, Berggren KL, Restrepo Cruz S, Gan GN, Beswick EJ. Inhibition of MK2 suppresses IL‐1β, IL‐6, and TNF‐α‐dependent colorectal cancer growth. Int J Cancer. 2018; 142(8):1702–1711. doi:10.1002/ijc.31191.
   PubMed Web of Science ®Google Scholar
• Terzić J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010; 138(6):2101–2114. doi:10.1053/j.gastro.2010.01.058.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Greten FR. The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol. 2021; 21(10):653–667. doi:10.1038/s41577-021-00534-x.
   PubMed Web of Science ®Google Scholar
• Triner D, Devenport SN, Ramakrishnan SK, Ma X, Frieler RA, Greenson JK, Inohara N, Nunez G, Colacino JA, Mortensen RM. Neutrophils restrict tumor-associated microbiota to reduce growth and invasion of colon tumors in mice. Gastroenterology. 2019; 156(5):1467–1482. doi:10.1053/j.gastro.2018.12.003.
   PubMed Web of Science ®Google Scholar
• Testro AG, Visvanathan K. Toll‐like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol. 2009; 24(6):943–954. doi:10.1111/j.1440-1746.2009.05854.x.
   PubMed Web of Science ®Google Scholar
• Duan X, Chan C, Lin W. Nanoparticle‐mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew Chem Int Ed. 2019; 58(3):670–680. doi:10.1002/anie.201804882.
   PubMed Web of Science ®Google Scholar
• Wu Z, Li S, Zhu X. The mechanism of stimulating and mobilizing the immune system enhancing the anti-tumor immunity. Front Immunol. 2021;12:682435. doi:10.3389/fimmu.2021.682435.
   PubMed Web of Science ®Google Scholar
• Adachi K, Tamada K. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci. 2015;106:945–950. doi:10.1111/cas.12695.
   PubMed Web of Science ®Google Scholar
• Cao Y, Wang X, Jin T, Tian Y, Dai C, Widarma C, Song R, Xu F. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduct Target Ther. 2020; 5(1):250. doi:10.1038/s41392-020-00348-8.
   PubMed Web of Science ®Google Scholar
• Li Y, Dong K, Fan X, Xie J, Wang M, Fu S, Li Q. DNT cell-based immunotherapy: progress and applications. J Cancer. 2020; 11(13):3717. doi:10.7150/jca.39717.
   PubMed Web of Science ®Google Scholar
• Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer. Am J Hematol. 2019; 94(S1):3–9. doi:10.1002/ajh.25418.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Deng J, Rao S, Guo S, Shen J, Du F, Wu X, Chen Y, Li M, Chen M. Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers. 2022; 14(17):4160. doi:10.3390/cancers14174160.
   PubMed Web of Science ®Google Scholar
• Oh S, Lee J-H, Kwack K, Choi S-W. Natural killer cell therapy: a new treatment paradigm for solid tumors. Cancers. 2019; 11(10):1534. doi:10.3390/cancers11101534.
   PubMed Web of Science ®Google Scholar
• Ma Y, Y-C X, Tang L, Zhang Z, Wang J, Wang H-X. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol. 2012; 1(1):1–10. doi:10.1186/2162-3619-1-11.
   PubMedGoogle Scholar
• Jaroslawski S, Caban A, Toumi M. Sipuleucel-T (Provenge®): Autopsy of an Innovative Change of Paradigm in Cancer Treatment. Value in Health. 2015; 18(7):A479. doi:10.1016/j.jval.2015.09.1294.
   Web of Science ®Google Scholar
• Constantino J, Gomes C, Falcão A, Neves BM, Cruz MT. Dendritic cell-based immunotherapy: a basic review and recent advances. Immunol Res. 2017; 65(4):798–810. doi:10.1007/s12026-017-8931-1.
   PubMed Web of Science ®Google Scholar
• Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018;834:188–196. doi:10.1016/j.ejphar.2018.07.034.
   PubMed Web of Science ®Google Scholar
• Banstola A, Jeong J-H, Yook S. Immunoadjuvants for cancer immunotherapy: A review of recent developments. Acta Biomater. 2020;114:16–30. doi:10.1016/j.actbio.2020.07.063.
   PubMed Web of Science ®Google Scholar
• Schmidt FM, Lichtblau N, Minkwitz J, Chittka T, Thormann J, Kirkby KC, Sander C, Mergl R, M F, Stumvoll M. Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity. J Psychiatr Res. 2014;55:29–34. doi:10.1016/j.jpsychires.2014.04.021.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–2788. doi:10.1200/JCO.2014.58.3377.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A. 1994;91:6458–6462. doi:10.1073/pnas.91.14.6458.
   PubMed Web of Science ®Google Scholar
• Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018; 24(7):994–1004. doi:10.1038/s41591-018-0057-z.
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372(26):2509–2520. doi:10.1056/NEJMoa1500596.
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Thielens A, Marabelle A, Sagiv-Barfi I, Sola C, Chanuc F, Fuseri N, Bonnafous C, Czerwinski D, Rajapaksa A. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014; 123(5):678–686. doi:10.1182/blood-2013-08-519199.
   PubMed Web of Science ®Google Scholar
• Loo K, Smithy JW, Postow MA, Betof Warner A. Factors determining long-term antitumor responses to immune checkpoint blockade therapy in melanoma. Front Immunol. 2022;12:810388. doi:10.3389/fimmu.2021.810388.
   PubMed Web of Science ®Google Scholar
• Levy Z. Can gut bacteria boost cancer treatments? Nature. 2022; 607(7919):436–439. doi:10.1038/d41586-022-01959-7.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The influence of the gut microbiome on cancer, immunity, and cancer immunotherapy. Cancer Cell. 2018; 33(4):570–580. doi:10.1016/j.ccell.2018.03.015.
   PubMed Web of Science ®Google Scholar
• Bonilla FA, Oettgen HC. Adaptive immunity. J Allergy Clin Immunol. 2010;125:S33–S40. doi:10.1016/j.jaci.2009.09.017.
   PubMed Web of Science ®Google Scholar
• Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350(6264):1079–1084. doi:10.1126/science.aad1329.
   PubMed Web of Science ®Google Scholar
• Routy B, Lenehan JG, Miller WH Jr, Jamal R, Messaoudene M, Daisley BA, Hes C, Al KF, Martinez-Gili L, Punčochář M. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: A phase I trial. Nat Med. 2023; 29(8):2121–2132. doi:10.1038/s41591-023-02453-x.
   PubMed Web of Science ®Google Scholar
• Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021; 371(6529):602–609. doi:10.1126/science.abb5920.
   PubMed Web of Science ®Google Scholar
• Davar D, Dzutsev AK, JA M, Rodrigues RR, Chauvin J-M, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O. et al. Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients. Science. 2021; 371(6529):595–602. doi:10.1126/science.abb5920.
   PubMed Web of Science ®Google Scholar
• Li H, van der Merwe PA, Sivakumar S, van der Merwe PA. Biomarkers of response to PD-1 pathway blockade. Br J Cancer. 2022; 126(12):1663–1675. doi:10.1038/s41416-022-01743-4.
   PubMed Web of Science ®Google Scholar
• McCulloch JA, Davar D, Rodrigues RR, Badger JH, Fang JR, Cole AM, Balaji AK, Vetizou M, Prescott SM, Fernandes MR. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat Med. 2022; 28(3):545–556. doi:10.1038/s41591-021-01655-5.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Man Lei Y, Jabri B, Alegre M-L. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science. 2015; 350(6264):1084–1089. doi:10.1126/science.aac4255.
   PubMed Web of Science ®Google Scholar
• Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of action of probiotics. Adv Nutr. 2019;10:S49–S66. doi:10.1093/advances/nmy063.
   PubMed Web of Science ®Google Scholar
• Solanki SS, Singh P, Kashyap P, Sansi MS, Ali SA. Promising role of defensins peptides as therapeutics to combat against viral infection. Microb Pathog. 2021;155:104930. doi:10.1016/j.micpath.2021.104930.
   PubMed Web of Science ®Google Scholar
• Li J, Sung CYJ, Lee N, Ni Y, Pihlajamäki J, Panagiotou G, El-Nezami H. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice. Proc Natl Acad Sci U S A. 2016;113:1306–1315. doi:10.1073/pnas.1518189113.
   PubMed Web of Science ®Google Scholar
• Van Zyl WF, Deane SM, Dicks LM. Molecular insights into probiotic mechanisms of action employed against intestinal pathogenic bacteria. Gut Microbes. 2020; 12(1):1831339. doi:10.1080/19490976.2020.1831339.
   PubMed Web of Science ®Google Scholar
• Monteagudo-Mera A, Rastall RA, Gibson GR, Charalampopoulos D, Chatzifragkou A. Adhesion mechanisms mediated by probiotics and prebiotics and their potential impact on human health. Appl Microbiol Biotechnol. 2019; 103(16):6463–6472. doi:10.1007/s00253-019-09978-7.
   PubMed Web of Science ®Google Scholar
• Liu Q, Yu Z, Tian F, Zhao J, Zhang H, Zhai Q, Chen W. Surface components and metabolites of probiotics for regulation of intestinal epithelial barrier. Microb Cell Fact. 2020; 19(1):1–11. doi:10.1186/s12934-020-1289-4.
   PubMed Web of Science ®Google Scholar
• Maldonado Galdeano C, Cazorla SI, Lemme Dumit JM, Vélez E, Perdigón G. Beneficial effects of probiotic consumption on the immune system. Ann Nutr Metab. 2019; 74(2):115–124. doi:10.1159/000496426.
   PubMed Web of Science ®Google Scholar
• Kang H-J, Im S-H. Probiotics as an immune modulator. J Nutr Sci Vitaminol (Tokyo). 2015;61:S103–S105. doi:10.3177/jnsv.61.S103.
   PubMed Web of Science ®Google Scholar
• Rocha-Ramírez L, Pérez-Solano R, Castañón-Alonso S, Moreno Guerrero S, Ramírez Pacheco A, García Garibay M, Eslava C. Probiotic Lactobacillus strains stimulate the inflammatory response and activate human macrophages. J Immunol Res. 2017;2017:1–14. doi:10.1155/2017/4607491.
   Web of Science ®Google Scholar
• Rinaldi E, Consonni A, Guidesi E, Elli M, Mantegazza R, Baggi F. Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis? Ann N Y Acad Sci. 2018; 1413(1):49–58. doi:10.1111/nyas.13567.
   PubMed Web of Science ®Google Scholar
• Sun S, Luo L, Liang W, Yin Q, Guo J, Rush AM, Lv Z, Liang Q, Fischbach MA, Sonnenburg JL. Bifidobacterium alters the gut microbiota and modulates the functional metabolism of T regulatory cells in the context of immune checkpoint blockade. Proc Natl Acad Sci U S A. 2020;117:27509–27515. doi:10.1073/pnas.1921223117.
   PubMed Web of Science ®Google Scholar
• Feleszko W, Jaworska J, Rha RD, Steinhausen S, Avagyan A, Jaudszus A, Ahrens B, Groneberg D, Wahn U, Hamelmann E. Probiotic‐induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory‐dependent mechanisms in a murine model of asthma. Clin Exp Allergy. 2007; 37(4):498–505. doi:10.1111/j.1365-2222.2006.02629.x.
   PubMed Web of Science ®Google Scholar
• Foligne B, Nutten S, Grangette C, Dennin V, Goudercourt D, Poiret S, Dewulf J, Brassart D, Mercenier A, Pot B. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol. 2007; 13(2):236–243. doi:10.3748/wjg.v13.i2.236.
   PubMed Web of Science ®Google Scholar
• Singh TP, Natraj BH. Next-generation probiotics: a promising approach towards designing personalized medicine. Crit Rev Microbiol. 2021;47:479–498. doi:10.1080/1040841X.2021.1902940.
   PubMed Web of Science ®Google Scholar
• O’Toole PW, Marchesi JR, Hill C. Next-generation probiotics: the spectrum from probiotics to live biotherapeutics. Nat Microb. 2017; 2(5):1–6. doi:10.1038/nmicrobiol.2017.57.
   Web of Science ®Google Scholar
• Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022; 28(2):315–324. doi:10.1038/s41591-021-01655-5.
   PubMed Web of Science ®Google Scholar
• Bullman S, Eggermont A, Johnston CD, Zitvogel L. Harnessing the microbiome to restore immunotherapy response. Nat Cancer. 2021; 2(12):1301–1304. doi:10.1038/s43018-021-00300-x.
   PubMedGoogle Scholar
• Le Noci V, Guglielmetti S, Arioli S, Camisaschi C, Bianchi F, Sommariva M, Storti C, Triulzi T, Castelli C, Balsari A. Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: a strategy to promote immunosurveillance against lung metastases. Cell Rep. 2018;24:3528–3538. doi:10.1016/j.celrep.2018.08.090.
   PubMed Web of Science ®Google Scholar
• Shi Y, Zheng W, Yang K, Harris KG, Ni K, Xue L, Lin W, Chang EB, Weichselbaum RR, Fu Y-X. Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling. J Exp Med. 2020; 217(5):e20192282. doi:10.1084/jem.20192282.
   PubMed Web of Science ®Google Scholar
• Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, Molina DA, Salcedo R, Back T, Cramer S. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013; 342(6161):967–970. doi:10.1126/science.1240527.
   PubMed Web of Science ®Google Scholar